Chronic dichlorvos exposure: Microglial activation, proinflammatory cytokines and damage to nigrostriatal dopaminergic system

NeuroMolecular Medicine

Volumn 13, Issue 4, 2011, Pages 251-265

  Binukumar, B K ^a   Bal, Amanjit ^a   Gill, Kiran Dip ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Dichlorvos; Microglia; Neurodegeneration; Neuroinflammation; Parkinson's disease

Indexed keywords

CD11B ANTIGEN; CELL MARKER; CYTOKINE; DICHLORVOS; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENZYME ACTIVATION; ENZYME INDUCTION; GENE; GENE EXPRESSION REGULATION; GP 91 PHOX GENE; LONG TERM EXPOSURE; MAC 1 GENE; MALE; MICROGLIA; NADPH OXIDASE GENE; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RISK ASSESSMENT; RISK FACTOR; SUBSTANTIA NIGRA; TRANSCRIPTION REGULATION;

ANIMALS; CHOLINESTERASE INHIBITORS; CORPUS STRIATUM; CYTOKINES; DICHLORVOS; DOPAMINERGIC NEURONS; ENVIRONMENTAL EXPOSURE; MALE; MICROGLIA; NADPH OXIDASE; PARKINSON DISEASE, SECONDARY; RATS; RATS, WISTAR; SUBSTANTIA NIGRA;

ANIMALIA; RATTUS;

EID: 84855890362     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-011-8156-8     Document Type: Article

References (58)

1. Banati, R. B., Daniel, S. E., & Blunt, S. B. (1998). Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Movement Disorders, 13(2), 221-227. (Pubitemid 28127795)
2. Barcia, C., de Pablos, V., Bautista-Hernandez, V., Sanchez-Bahillo, A., Bernal, I., & Fernandez-Villalba, E. (2005). Increased plasma levels of TNF-alpha but not of IL1-beta in MPTP-treated monkeys one year after the MPTP administration. Parkinsonism and Related Disorders, 11, 435-439. (Pubitemid 41526994)
3. Binukumar, B. K., Bal, A., Kandimalla, R. J., & Gill, K. D. (2010). Nigrostriatal neuronal death following chronic dichlorvos exposure: crosstalk between mitochondrial impairments, alpha synuclein aggregation, oxidative damage and behavioral changes. Molecular Brain, 3(1), 35.
4. Block, M. L., Zecca, L., & Hong, J. S. (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience, 8, 57-69. (Pubitemid 46011999)
5. Boka, G., Anglade, P., Wallach, D., Javoy-Agid, F., & Agid, Y. (1994). Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neuroscience Letters, 172, 151-154. (Pubitemid 24178765)
6. Brodacki, B., Staszewski, J., Toczylowska, B., Kozlowska, E., & Drela, N. (2008). Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neuroscience Letters, 441, 158-162.
7. Cardona, A. E., Huang, D., Sasse, M. E., & Ransohoff, R. M. (2006). Isolation of murine microglial cells for RNA analysis or flow cytometry. Nature Protocols, 1(4), 1947-1951. (Pubitemid 46773316)
8. Carvey, P. M., Chen, E. Y., Lipton, J. W., Tong, C. W., Chang, Q. A., & Ling, Z. D. (2005). Intra-parenchymal injection of tumor necrosis factor-alpha and interleukin 1-beta produces dopamine neuron loss in the rat. Journal of Neural Transmission, 112, 601-612. (Pubitemid 40591194)
9. Chen, H., Jacobs, E., Schwarzschild, M. A., McCullogh, M. L., Calle, E. E., Thun, M. J., et al. (2005). Nonsteroidal anti-inflammatory drug use and the risk for Parkinson's disease. Annals of Neurology, 58, 963-967. (Pubitemid 41746889)
10. Fahn, S. (2003). Description of Parkinson's disease as a clinical syndrome. Annals of the New York Academy of Sciences, 991, 1-14. (Pubitemid 36793796)
11. Ferger, B., Leng, A., Mura, A., Hengerer, B., & Feldon, J. (2004). Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. Journal of Neurochemistry, 89(4), 822-833. (Pubitemid 38684730)
12. Ferrer, I., Blanco, R., Carmona, M., Puig, B., & Barrachina, M. (2001). Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies. Journal of Neural Transmission, 108, 1383-1396. (Pubitemid 34020444)
13. Gao, H. M., Liu, B., & Hong, J. S. (2003a). Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. Journal of Neuroscience, 23, 6181-61817.
14. Gao, H. M., Liu, B., Zhang, W., & Hong, J. S. (2003b). Critical role of microglial NADPH oxidase-derived free radicals in the MPTP model of parkinson's disease. FASEB Journal, 17(13), 1954-1956.
15. Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., & Es, M. (2006). In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiology of Diseases, 21, 404-412. (Pubitemid 43099863)
16. Green, S. P., Cairns, B., Rae, J., Errett-Baroncini, C., Hongo, J. A., & Erickson, R. W. (2001). Induction of gp91-phox, a component of the phagocyte NADPH oxidase, in microglial cells during central nervous system inflammation. Journal of Cerebral Blood Flow and Metabolism, 21, 374-384. (Pubitemid 32298884)
17. Greenamyre, J. T., MacKenzie, G. M., Peng, T. I., & Stephans, S. E. (1999). Mitochondrial dysfunction in Parkinsonsís disease. Biochemical Society symposium, 66, 85-97.
18. Hald, A., & Lotharius, J. (2005). Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Experimental Neurology, 193, 279-290. (Pubitemid 40616179)
19. Hartmann, A., Troadec, J. D., Hunot, S., Kikly, K., & Faucheux, B. A. (2001). Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. Journal of Neuroscience, 21, 2247-2255. (Pubitemid 32240523)
20. Hasegawa, E., Takeshige, K., Oishi, T., Murai, Y., & Minakami, S. (1990). 1-Methyl-4-phenylpyridinium (MPP) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochemical and Biophysical Research Communications, 170, 1049-1055. (Pubitemid 20273373)
21. Hunot, S., Dugas, N., Faucheux, B., Hartmann, A., & Tardieu, M. (1999). Fcepsilon RII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. Journal of Neuroscience, 19, 3440-3447. (Pubitemid 29203124)
22. Kaur, P., Radotra, B., Minz, R. W., & Gill, K. D. (2007). Impaired mitochondrial energy metabolism and neuronal apoptotic cell death after chronic dichlorvos (OP) exposure in rat brain. Neurotoxicology, 28, 1208-1219. (Pubitemid 350026599)
23. Kim, W. G., Mohney, R. P., Wilson, B., Jeohn, G. H., Liu, B., & Hong, J. S. (2000). Regional difference in susceptibility to lipopolysaccharide- induced neurotoxicity in the rat brain: role of microglia. Journal of Neuroscience, 20, 6309-6316. (Pubitemid 30658427)
24. Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999). Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine exposure. Annals of Neurology, 46, 598-605. (Pubitemid 29466438)
25. Lawson, L. J., Perry, V. H., Dri, P., & Gordon, S. (1990). Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience, 39, 151-170.
26. Ling, Z., Gayle, D. A., Ma, S. Y., Lipton, J. W., Tong, C. W., & Hong, J. S. (2002). In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Movement Disorders, 17, 116-124. (Pubitemid 36041267)
27. Liou, H., Tsai, M., Chen, C. J., & Jeng, J. (1997). Environmental risk factors for Parkinson's disease: a case control study in Taiwan. Neurology, 48, 1583-1588.
28. Lowry, O. H., Rosebrough, N. J., Farr, A. L., & Randall, R. J. (1951). Protein measurement with the folin-phenol reagent. Journal of Biological Chemistry, 193, 265-275.
29. Manning-Bog, A. B., McCormack, A. L., Li, J., Uversky, V. N., Fink, A. L., & Di Monte, D. A. (2002). The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. Journal of Biological Chemistry, 277(3), 1641-1644. (Pubitemid 34968732)
30. Mayeux, R. (2003). Epidemiology of neurodegeneration. Annual Review of Neuroscience, 26, 81-104. (Pubitemid 37064929)
31. McCormack, A. L., Thiruchelvam, M., Manning-Bog, A. B., Thiffault, C., Langston, J. W., Cory-Slechta, D. A., et al. (2002). Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiology of Diseases, 10(2), 119-127. (Pubitemid 34775465)
32. McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988). Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 38, 1285-1291.
33. McGeer, P. L., & McGeer, E. G. (2004). Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism and Related Disorders, 10(suppl 1), S3-S7. (Pubitemid 38510423)
34. McGeer, P. L., Yasojima, K., & McGeer, E. G. (2002). Association of interleukin-1 beta polymorphisms with idiopathic Parkinson's disease. Neuroscience Letters, 326, 67-69. (Pubitemid 34607596)
35. Mogi, M., Harada, M., Riederer, P., Narabayashi, H., & Fujita, K. (1994). Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neuroscience Letters, 165, 208-210.
36. Mogi, M., Togari, A., Kondo, T., Mizuno, Y., & Komure, O. (2000). Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. Journal of Neural Transmission, 107, 335-341. (Pubitemid 30162695)
37. Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., & Kanno, T. (2005). Microglial activation and dopamine terminal loss in early Parkinson's disease. Annals of Neurology, 57, 168-175. (Pubitemid 40179853)
38. Parvathenani, L. K., Tertyshnikova, S., Greco, C. R., Roberts, S. B., Robertson, B., & Posmantur, R. (2003). P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. Journal of Biological Chemistry, 278, 13309-13317. (Pubitemid 36800102)
39. Paxinos, G., & Watson, C. (1986). The rat brain in stereotaxic coordinates. London: Academic Press.
40. Priyadarshi, A., Khuder, S. A., Schaub, E. A., & Priyadarshi, S. S. (2001). Environmental risk factors and Parkinson's disease: a metaanalysis. Environmental Research, 86(2), 122-127. (Pubitemid 32656305)
41. Rajput, A. H., Uitti, R. J., & Stern, W. (1987). Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson's disease. Canadian Journal of Neurological Sciences, 14, 414-418. (Pubitemid 17147624)
42. Rousselet, E., Callebert, J., Parain, K., Joubert, C., Hunot, S., & Hartmann, A. (2002). Role of TNF-alpha receptors in mice intoxicated with the Parkinsonian toxin MPTP. Experimental Neurology, 177, 183-192. (Pubitemid 35356832)
43. Sawada, M., Imamura, K., & Nagatsu, T. (2006). Role of cytokines in inflammatory process in Parkinson's disease. Journal of Neural Transmission Supplementum, 70, 373-381. (Pubitemid 44622226)
44. Schapira, A. H. (2007). Mitochondrial dysfunction in Parkinson's disease. Cell Death and Differentiation, 14, 1261-1266. (Pubitemid 46965257)
45. Schulte, T., Schols, L., Muller, T., Woitalla, D., Berger, K., & Kruger, R. (2002). Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease. Neuroscience Letters, 326, 70-72. (Pubitemid 34607597)
46. Semchuk, K. M., Love, E. J., & Lee, R. G. (1992). Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology, 42(7), 1328-1335.
47. Sherer, T. B., Betarbet, R., Kim, J. H., & Greenamyre, J. T. (2003). Selective microglial activation in the rat rotenone model of Parkinson's disease. Neuroscience Letters, 341, 87-90. (Pubitemid 36398476)
48. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997). Synuclein in Lewy bodies. Nature, 388, 839-840.
49. Sriram, K., Matheson, J. M., Benkovic, S. A., Miller, D. B., Luster, M. I., & O'Callaghan, J. P. (2002). Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB Journal, 16, 1474-1476.
50. Stone, T. W., & Behan, W. M. (2007). Interleukin-1beta but not tumor necrosis factor-alpha potentiates neuronal damage by quinolinic acid: protection by an adenosine A2A receptor antagonist. Journal of Neuroscience Research, 85, 1077-1085. (Pubitemid 46580348)
51. Teismann, P., & Schulz, J. B. (2004). Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell and Tissue Research, 318, 149-161. (Pubitemid 39362635)
52. Thiruchelvam, M., McCormack, A., Richfield, E. K., Baggs, R. B., Tank, A. W., Di Monte, D. A., et al. (2003). Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. European Journal of Neuroscience, 18(3), 589-600. (Pubitemid 37045378)
53. Thiruchelvam, M., Richfield, E. K., Baggs, R. B., Tank, A. W., & Cory-Slechta, D. A. (2000). The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. Journal of Neuroscience, 20(24), 9207-9214. (Pubitemid 32042923)
54. Thiruchelvam, M., Richfield, E. K., Goodman, B. M., Baggs, R. B., & Cory-Slechta, D. A. (2002). Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. Neurotoxicology, 23(4-5), 621-633. (Pubitemid 36527682)
55. Turrens, J. F., & Boveris, A. (1980). Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochemical Journal, 191, 421-427.
56. Van Den Eeden, S. K., Tanner, C. M., Bernstein, A. L., Fross, R. D., Leimpeter, A., Bloch, D. A., et al. (2003). Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. American Journal of Epidemiology, 157, 1015-1022. (Pubitemid 36628805)
57. Wooten, G. F. (1997). Neurochemistry and neuropharmacology of Parkinson's disease. In R. L. Watts & W. C. Koller (Eds.), Movement disorders: neurologic principles and practice (pp. 153-160). New York: McGraw-Hill.
58. Wu, D. C., Teismann, P., Tieu, K., Vila, M., Jackson-Lewis, V., Ischiropoulos, H., et al. (2003). NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 100, 6145-6150. (Pubitemid 36576945)